Suppr超能文献

布托啡诺鼻喷雾剂在肾功能损害患者中的药代动力学。

Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.

作者信息

Shyu W C, Morgenthien E A, Barbhaiya R H

机构信息

Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Lawrenceville, NJ 08543-4000, USA.

出版信息

Br J Clin Pharmacol. 1996 May;41(5):397-402. doi: 10.1046/j.1365-2125.1996.03327.x.

Abstract
  1. The pharmacokinetics of butorphanol were evaluated in 18 female volunteers with varying degrees of renal function following a single, 1 mg transnasal dose of butorphanol tartrate. The creatinine clearance (CLCR) values for subjects in the normal (NOR), moderately impaired (MI), and severely impaired (SI) groups were > or = 70 ml min-1, 30-60 ml min-1, and < or = 30 ml min-1, respectively. 2. Serial blood and urine samples were collected immediately after dosing for 48 h. Plasma concentrations of butorphanol were determined using a specific radioimmunoassay. Urine concentrations of butorphanol and its metabolites (hydroxy-butorphanol, norbutorphanol and their glucuronide conjugates) were determined using h.p.l.c. with fluorescence detection. 3. There was no significant difference between the three treatments for peak plasma concentration of butorphanol and time to peak. Statistically significant differences were detected among the study groups for AUC, t1/2, MRT, and CLR with the mean values for severely impaired subjects significantly different from those of normal renal subjects; mean values for moderately impaired subjects were not significantly different from either the normal or severely impaired groups for all respective parameters. 4. The elimination half-life of butorphanol increased from 5.75 h in NOR to 10.48 h in SI. A similar trend was observed for MRT. Creatinine clearance (CLCR) significantly correlated with CLR (r = 0.563, P = 0.019), CLT/F (r = 0.505, P = 0.033), t1/2 (r = -0.554, P = 0.017) and lambda (r = 0.606, P = 0.008). 5. Although the exposure of butorphanol was greater in subjects with renal impairment, there was no trend for an increase in the number of adverse experiences reported by subjects with renal dysfunction. 6. Patients with less than 30 ml min-1 creatinine clearance may require less frequent administration of transnasal butorphanol as compared with subjects with normal or moderately impaired renal function.
摘要
  1. 在18名肾功能程度各异的女性志愿者中,给予单次1毫克经鼻剂量的酒石酸布托啡诺后,评估了布托啡诺的药代动力学。正常(NOR)组、中度受损(MI)组和重度受损(SI)组受试者的肌酐清除率(CLCR)值分别≥70毫升/分钟、30 - 60毫升/分钟和≤30毫升/分钟。2. 给药后立即连续采集48小时的血液和尿液样本。使用特异性放射免疫分析法测定血浆中布托啡诺的浓度。使用带有荧光检测的高效液相色谱法测定尿液中布托啡诺及其代谢物(羟基布托啡诺、去甲布托啡诺及其葡萄糖醛酸结合物)的浓度。3. 三种治疗方法在布托啡诺的血浆峰浓度和达峰时间方面无显著差异。研究组之间在AUC、t1/2、MRT和CLR方面检测到统计学显著差异,重度受损受试者的平均值与正常肾功能受试者的平均值显著不同;中度受损受试者的所有相应参数平均值与正常或重度受损组均无显著差异。4. 布托啡诺的消除半衰期从NOR组的5.75小时增加到SI组的10.48小时。MRT也观察到类似趋势。肌酐清除率(CLCR)与CLR(r = 0.563,P = 0.019)、CLT/F(r = 0.505,P = 0.033)、t1/2(r = -0.554,P = 0.017)和lambda(r = 0.606,P = 0.008)显著相关。5. 尽管肾功能受损受试者中布托啡诺的暴露量更大,但肾功能不全受试者报告的不良经历数量没有增加趋势。6. 与肾功能正常或中度受损的受试者相比,肌酐清除率低于30毫升/分钟的患者可能需要减少经鼻布托啡诺的给药频率。

相似文献

3
The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.
Biopharm Drug Dispos. 1997 Apr;18(3):191-202. doi: 10.1002/(sici)1099-081x(199704)18:3<191::aid-bdd9>3.0.co;2-6.
7
Multiple-dose phase I study of transnasal butorphanol.
Clin Pharmacol Ther. 1993 Jul;54(1):34-41. doi: 10.1038/clpt.1993.106.
8
Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
J Clin Pharmacol. 1995 Apr;35(4):432-7. doi: 10.1002/j.1552-4604.1995.tb04085.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验